JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review of Sustainable Paradigms in Contemporary Drug Discovery and Development

Syed Ansar Ahmed*[1], Navabsab Shadulsab Pinjari[2]

[1]*Associate Professor, Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded Maharashtra, India*
[2]*Assistant Professor, Ramesh Patil Institute of Pharmacy, Khandgaon(Bendri), Naigaon District, Nanded Maharashtra, India*

Publication history: Received on 25th Jan 2025; Revised on 5th Feb 2025; Accepted on 8th Feb 2025

Article DOI: 10.69613/a500k960

Abstract: Pharmaceutical innovation faces unprecedented challenges in balancing therapeutic advancement with environmental stewardship. This article examines sustainable approaches that are revolutionizing drug discovery and development processes. The pharmaceutical industry, traditionally resource-intensive and environmentally burdensome, is undergoing a significant transformation through green chemistry principles, artificial intelligence integration, and circular economy frameworks. Innovative methodologies including biocatalysis, flow chemistry, solvent optimization, and computational modeling have substantially reduced hazardous waste production while improving efficiency. Simultaneously, pharmaceutical organizations are redesigning manufacturing processes to minimize environmental footprints through recycling initiatives, energy efficiency measures, and water conservation techniques. These shifts are complemented by regulatory frameworks that increasingly incentivize sustainability through updated guidelines and collaborative public-private partnerships. Drug lifecycle management has evolved to incorporate environmental considerations from discovery through post-market surveillance. Despite notable progress, implementation barriers persist, including economic constraints, technical limitations, and organizational resistance. The future trajectory points toward integrated sustainability metrics in drug approval processes, expanded bio-based technologies, enhanced transparency in environmental impact reporting, and collaborative ecosystems that bridge industry-academia-regulatory divides. This paradigm shift represents not merely environmental compliance but strategic advantage in an era where sustainability increasingly influences stakeholders across healthcare systems worldwide.

Keywords: Green chemistry; Sustainable pharmaceutical manufacturing; Artificial Intelligence; Circular economy; Environmental risk assessment.

1. Introduction

The pharmaceutical industry stands at a critical point where innovation must coincide with environmental responsibility. Traditional drug discovery and development paradigms, while successful in delivering life-saving medications, have been characterized by resource-intensive processes, significant waste generation, and substantial environmental impacts [1]. These conventional approaches have relied heavily on petroleum-derived compounds, toxic solvents, energy-intensive reactions, and linear production models that prioritize therapeutic outcomes with limited consideration of environmental consequences [2].

The environmental footprint of pharmaceutical development extends across multiple dimensions. Active pharmaceutical ingredients (APIs) entering aquatic ecosystems through manufacturing effluents and human excretion have demonstrated ecological toxicity at even trace concentrations [3]. Manufacturing processes generate hazardous waste at ratios significantly exceeding other chemical industries, with estimates suggesting that pharmaceutical production can generate between 25 and 100 kg of waste for each kilogram of API produced [4]. Furthermore, the carbon footprint associated with energy-intensive research, development, and manufacturing facilities contributes substantially to greenhouse gas emissions [5].

Recent decades have witnessed growing recognition of these challenges, catalyzing a fundamental shift toward sustainable approaches throughout the pharmaceutical value chain. This transition is driven by multiple converging factors: increasing regulatory scrutiny of environmental impacts, stakeholder demands for corporate environmental responsibility, economic imperatives for resource efficiency, and the scientific community's evolving ethical frameworks [6]. Consequently, pharmaceutical organizations are increasingly integrating sustainability principles into core research and development strategies rather than treating environmental considerations as peripheral compliance issues [7].

* Corresponding author: Syed Ansar Ahmed and Navabsab Shadulsab Pinjari

The scientific literature demonstrates clear progress in developing methods that simultaneously enhance therapeutic innovation while reducing environmental impacts. Green chemistry principles have transformed synthetic pathways [8], computational approaches have revolutionized hit identification and optimization processes [9], and manufacturing innovations have dramatically improved resource efficiency [10]. These advances suggest the possibility of a pharmaceutical paradigm where environmental and therapeutic objectives are harmonized rather than opposed. The main of this article is to study the current sustainable approaches across the pharmaceutical value chain, from early discovery through manufacturing and product lifecycle management.



Figure 1. Sustainable Pharmaceutical Development

2. Integration of Green Chemistry in Drug Discovery

2.1. Principles

Green chemistry fundamentally reimagines pharmaceutical discovery through systematic application of principles that minimize hazardous substances while maximizing efficiency. The twelve principles articulated by Anastas and Warner [11] have provided the foundational framework guiding sustainable transformations across discovery platforms. These principles emphasize waste prevention, atom economy, safer solvent selection, energy efficiency, renewable feedstocks, and inherently safer chemistry. The implementation of these principles in pharmaceutical discovery contexts has yielded notable advances. Researchers at GlaxoSmithKline developed environmental assessment tools that integrate green chemistry metrics into decision-making processes during candidate selection [12]. Similarly, Pfizer implemented a solvent selection guide that categorizes solvents based on environmental, health, and safety parameters, facilitating informed choices during reaction development [13]. These systematic

approaches enable comparative assessment of synthetic routes using sustainability metrics alongside traditional parameters like yield and purity.

The pharmaceutical industry has witnessed significant improvements through green chemistry applications. For instance, the redesign of sertraline (Zoloft) manufacturing eliminated titanium tetrachloride and dichloroethane, reduced solvent usage by 60%, and improved overall efficiency [14]. Similarly, sitagliptin (Januvia) production was transformed by introducing an engineered transaminase enzyme that eliminated the need for high-pressure hydrogenation equipment, reduced waste by 19%, and improved productivity by 56% [15].

2.2. Biocatalysis

Biocatalysis represents a transformative approach to pharmaceutical synthesis that harnesses nature's catalytic machinery. Enzymes perform complex transformations under mild conditions with exceptional selectivity, significantly reducing energy requirements and waste generation. The pharmaceutical industry increasingly utilizes engineered enzymes to catalyze reactions that traditionally required metal catalysts, protecting groups, and hazardous reagents [16].

Recent advances in protein engineering, directed evolution, and computational design have dramatically expanded the biocatalytic toolkit available to pharmaceutical scientists. Frances Arnold's pioneering work on directed evolution has enabled the creation of enzymes performing reactions unknown in biological systems, opening new synthetic possibilities [17]. These approaches have enabled commercially viable enzymatic processes that significantly outperform conventional methods on sustainability metrics.

The case of letermovir (Prevymis), an antiviral medication, demonstrates biocatalysis advantages. Researchers developed an enzymatic cascade to replace a seven-step chemical synthesis, eliminating multiple purification operations, reducing solvent usage by 93%, and improving overall yield [18]. Similarly, an engineered ketoreductase enabled asymmetric ketone reduction in sitagliptin manufacturing, eliminating rhodium-based catalysts and high-pressure equipment while improving yield and stereoselectivity [19]

Table 1. Traditional vs. Green Chemistry Approaches in Pharmaceutical Synthesis

Parameter	Traditional Approach	Green Chemistry Approach	Environmental Impact Reduction
Solvent Usage	Chlorinated solvents (DCM, chloroform) Dipolar aprotic solvents (DMF, NMP)	Bio-derived solvents (2-MeTHF, ethyl lactate) Aqueous systems Supercritical CO_2	60-95% reduction in solvent waste 80-90% reduction in toxic solvent emissions Decreased remediation requirements
Catalyst Systems	Heavy metal catalysts (Pd, Pt, Rh) Stoichiometric metal reagents Homogeneous systems	Heterogeneous catalysts Enzyme catalysts Metal-free organocatalysis	70-95% reduction in metal waste Elimination of heavy metal contamination Decreased purification requirements
Reaction Conditions	High temperature (>100°C) High pressure (>10 bar) Cryogenic conditions	Ambient temperature (20-40°C) Atmospheric pressure Physiological conditions	40-80% reduction in energy consumption Decreased equipment requirements Improved safety profile
Protecting Group Strategy	Multiple protection/deprotection steps Functional group manipulations Linear syntheses	Direct functionalization C-H activation Convergent syntheses	30-70% reduction in step count 50-80% improvement in atom economy Decreased waste from auxiliary reagents
Purification Methods	Multiple crystallizations Column chromatography Distillation	Crystallization from green solvents Membrane filtration Simulated moving bed chromatography	50-80% reduction in purification solvent Decreased adsorbent waste Improved product recovery

2.3. Flow Chemistry

Flow chemistry represents a paradigm shift from traditional batch processing toward continuous manufacturing systems that offer significant sustainability advantages. In flow systems, reactions occur in channels or tubes as reagents move through the reactor, enabling precise control over reaction parameters, improved heat transfer, and enhanced safety profiles [20]. These characteristics make flow chemistry particularly valuable for hazardous transformations that present safety challenges in batch processes.

Pharmaceutical applications of flow chemistry demonstrate multiple sustainability benefits. Researchers at Massachusetts Institute of Technology developed an integrated continuous manufacturing system for aliskiren hemifumarate that reduced the manufacturing

footprint by 90%, cut production time from weeks to days, and significantly decreased solvent consumption [21]. Similarly, continuous manufacturing of prexasertib monohydrochloride reduced total manufacturing time by 60% and improved mass efficiency through solvent reduction [22].

Flow chemistry particularly excels in enabling reactions requiring hazardous intermediates or extreme conditions. Photochemical transformations that traditionally demanded specialized equipment and extensive energy inputs have been successfully translated to flow formats with LED light sources, dramatically reducing energy consumption while improving safety profiles [23]. Similarly, electrochemical transformations in flow systems eliminate many reagents while providing selective oxidation or reduction under mild conditions [24].

2.4. Solvent Selection and Optimization

Solvents constitute the majority of materials used in pharmaceutical processes, representing a critical sustainability focus area. Traditional pharmaceutical synthesis has relied heavily on chlorinated and petroleum-derived solvents with significant environmental and health concerns [25]. Sustainable approaches systematically replace these problematic solvents with environmentally benign alternatives or redesign processes to minimize solvent requirements. Comprehensive solvent selection guides developed by pharmaceutical companies provide systematic frameworks for evaluating and selecting solvents based on environmental, health, safety, and regulatory considerations [26]. These guides typically categorize solvents into preferred, acceptable, and undesirable classifications, guiding chemists toward more sustainable choices during method development. For instance, AstraZeneca's solvent selection guide prioritizes solvents based on waste, health, safety, environmental, and life cycle assessment parameters [27].

Beyond simple substitution, innovative approaches include: (1) supercritical carbon dioxide as a non-toxic, recyclable reaction medium for various transformations; (2) water-based chemistry that eliminates organic solvents entirely for compatible reactions; and (3) ionic liquids with negligible vapor pressure that reduce volatile organic compound emissions [28]. Additionally, solvent-free methodologies utilizing mechanochemistry (reaction induction through mechanical force) have demonstrated viability for multiple pharmaceutical transformations [29]. Recent advances include switchable solvent systems that change properties under different conditions, enabling easier separation and recovery [30]. The pharmaceutical industry has documented numerous successful solvent optimizations, including Bristol-Myers Squibb's redesign of a key biaryl coupling in BMS-777607 synthesis that replaced dichloromethane with 2-methyltetrahydrofuran, reducing process mass intensity by 86% [31]

3. Artificial Intelligence

3.1. Virtual Screening and Target Identification

Computational methods have revolutionized the earliest stages of drug discovery, enabling virtual exploration of chemical space with minimal material resources. Structure-based virtual screening uses three-dimensional protein structures to identify molecules likely to interact with therapeutic targets, while ligand-based approaches identify compounds similar to known actives [32]. These approaches dramatically reduce the number of compounds requiring physical synthesis and testing, substantially decreasing material consumption and waste generation.

The environmental benefits of computational screening are substantial. Traditional high-throughput screening consumes significant material resources, including plastic consumables, reagents, solvents, and energy inputs. Each screening plate typically requires disposal after single use, generating substantial plastic waste [33]. In contrast, virtual screening can evaluate millions of compounds using computational resources alone, with physical testing reserved for the most promising candidates.

Recent applications demonstrate the power of these approaches. Researchers at Novartis utilized machine learning-enhanced virtual screening to identify novel antimalarial compounds, reducing the number of compounds requiring synthesis by approximately 95% compared to conventional approaches [34]. Similarly, structure-based virtual screening identified starting points for COVID-19 therapeutics, accelerating discovery while minimizing laboratory resource consumption during pandemic response [35].

3.2. Molecular Modeling and Simulation

Advanced simulation techniques have transformed rational drug design by providing atomic-level insights into protein-ligand interactions. Molecular dynamics simulations model the time-dependent behavior of biological systems, revealing binding kinetics, conformational changes, and energetic profiles that guide optimization efforts [36]. These computational approaches enable more focused optimization campaigns that require fewer synthesized compounds to achieve desired properties.

Simulation methodologies have demonstrated particular value in optimizing pharmacokinetic properties, which traditionally required extensive animal testing. Computational approaches including physiologically-based pharmacokinetic (PBPK) modeling predict compound behavior in biological systems, enabling rational design of molecules with improved distribution, metabolism, and excretion profiles [37]. These methods reduce reliance on animal models during early development while improving candidate quality.



Figure 2. Integration of AI in Pharmaceutical Development

Free energy perturbation calculations exemplify how computational methods enhance efficiency. These approaches calculate binding energy changes resulting from structural modifications, guiding medicinal chemists toward the most promising structural alterations [38]. Merck researchers applied these methods to optimize inhibitors for BACE-1, reducing the number of synthesized compounds by approximately 70% compared to traditional medicinal chemistry approaches [39].

3.3. Machine Learning in Property Prediction

Machine learning algorithms have transformed property prediction by identifying complex patterns in pharmaceutical datasets that extend beyond traditional structure-activity relationships. These approaches rapidly predict multiple parameters, including biological activity, toxicity, solubility, and metabolic stability, enabling multiparameter optimization with reduced experimental burden [40].

Deep learning architectures, particularly graph neural networks that capture molecular topology, have demonstrated exceptional predictive performance across diverse property domains [41]. These models integrate heterogeneous data sources, including structural, genomic, and phenotypic information, to build comprehensive predictive frameworks. The environmental benefits derive from focused synthesis campaigns targeting compounds with higher success probability, thereby reducing material consumption associated with failed candidates.

Practical applications demonstrate significant efficiency improvements. AstraZeneca implemented machine learning models predicting absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, reducing in vitro testing requirements by approximately 50% [42]. Similarly, Janssen Pharmaceuticals deployed deep learning models to predict cytochrome P450 enzyme interactions, achieving predictive accuracy comparable to experimental methods while eliminating biological reagent consumption [43].

3.4. Generative Chemistry and De Novo Design

Generative models represent the frontier of computational drug discovery, creating novel molecular structures optimized for multiple parameters simultaneously. These approaches use deep learning architectures, including variational autoencoders, generative adversarial networks, and transformer models, to navigate chemical space and generate structures with specified properties [44]. The environmental advantage lies in creating purpose-designed molecules rather than screening enormous libraries of pre-existing compounds.

Recent implementations demonstrate remarkable capabilities. Researchers at Insilico Medicine utilized generative adversarial networks to design novel DDR1 kinase inhibitors with desired properties, advancing from computer-generated structures to validated active compounds in just 46 days [45]. Similarly, Exscientia's AI-designed drug DSP-1181 for obsessive-compulsive

disorder progressed from project initiation to clinical candidate in 12 months, approximately 75% faster than traditional approaches [46].

Beyond generating individual molecules, these approaches design synthetic pathways utilizing green chemistry principles. Researchers at Carnegie Mellon University developed retrosynthesis planning algorithms that prioritize routes using green chemistry metrics, identifying pathways with reduced environmental impact [47]. These systems consider reaction efficiency, solvent selection, and reagent hazards alongside traditional synthetic feasibility parameters.

Table 2. Benefits of Computational Methods in Drug Discovery

Computational Method	Traditional Alternative	Resource Reduction	Efficiency Improvement	Case Study Evidence
Virtual Screening	High-throughput screening (HTS)	90-99% reduction in compounds synthesized 95-98% reduction in plastic consumables 80-90% reduction in reagent usage	5-10× faster hit identification 3-5× higher hit rate quality	Merck's β-secretase inhibitor program: 70% reduction in compounds tested with 2× higher hit rate AstraZeneca's GPCR program: 94% reduction in physical screening with equivalent hit discovery
Molecular Dynamics	X-ray crystallography Binding assays	60-80% reduction in protein production 70-90% reduction in crystallization attempts 50-70% reduction in binding assays	2-4× faster binding mode prediction 3-5× more binding poses evaluated	Pfizer's kinase inhibitor optimization: 65% fewer synthesized analogs Novartis's ligand optimization: 40% reduction in synthesis cycles
Quantum Mechanics	Empirical reaction optimization	50-80% reduction in reaction iterations 60-85% reduction in reagent consumption 40-70% reduction in waste generation	3-6× faster reaction optimization 10-50× more reaction conditions evaluated	GSK's catalytic reaction development: 70% reduction in laboratory experiments Bristol-Myers Squibb's synthesis route: 60% fewer experimental iterations
Machine Learning for ADMET	In vitro ADMET screening Animal PK studies	40-70% reduction in in vitro assays 30-60% reduction in animal studies 50-75% reduction in analytical resources	5-20× faster property prediction Earlier compound triaging Multi-parameter optimization	Janssen's toxicity prediction: 50% reduction in early toxicity testing AstraZeneca's DMPK platform: 45% reduction in in vitro testing
Generative Design	Medicinal chemistry iterations	60-85% reduction in synthesis cycles 50-80% reduction in optimization compounds 40-70% reduction in lead optimization time	3-10× more chemical space exploration Simultaneous multi-parameter optimization Novel scaffold identification	Insilico Medicine's DDR1 inhibitor: 46 days from generation to active compound Exscientia's OCD drug: 12 months vs. industry average of 4.5 years

4. Sustainable Manufacturing Innovations

4.1. Process Intensification and Efficiency

Process intensification combines multiple unit operations into integrated systems that reduce equipment footprint, energy consumption, and material requirements. This approach reimagines pharmaceutical manufacturing by emphasizing multifunctional equipment, novel energy transfer mechanisms, and alternative processing methods [48]. The environmental benefits include reduced facility size, decreased energy consumption, and improved mass transfer efficiency.



Figure 3. Sustainable Pharmaceutical Manufacturing Life Cycle

Practical implementations demonstrate substantial sustainability improvements. Novartis developed a continuous manufacturing platform for aliskiren that integrated reaction, crystallization, filtration, and drying operations into a single connected process, reducing manufacturing footprint by 90% and energy consumption by 50% [49]. Similarly, Eli Lilly implemented an integrated continuous manufacturing system for ozanimod that eliminated multiple solvent exchanges and crystallization steps, reducing process mass intensity by 77% [50].

Microreactor technology exemplifies process intensification advantages. These miniaturized reaction vessels provide exceptional heat and mass transfer characteristics, enabling reactions under precisely controlled conditions that maximize selectivity while minimizing byproduct formation [51]. Applications include exothermic hazardous reactions that traditionally required extensive safety measures, where microreactors provide inherently safer processing with improved yield and reduced waste generation.

4.2. Circular Economy Approaches and Materials Recovery

Circular economy principles transform pharmaceutical manufacturing from linear take-make-dispose models toward closed-loop systems where materials maintain value throughout multiple cycles. These approaches emphasize solvent recovery, catalyst regeneration, and byproduct valorization to minimize virgin material consumption and waste generation [52]. The pharmaceutical industry has increasingly implemented these principles through systematic programs targeting high-volume materials.

Solvent recovery represents the most established circular approach in pharmaceutical manufacturing. Advanced distillation technologies, membrane separations, and adsorption systems enable solvent purification for reuse in subsequent manufacturing campaigns [53]. Johnson & Johnson documented a comprehensive solvent recovery program that reclaimed over 70% of process solvents, reducing virgin solvent purchase by approximately 60% across manufacturing operations [54].

Catalyst recovery systems demonstrate similar benefits for precious metal catalysts used in pharmaceutical synthesis. Continuous-flow hydrogenation systems with immobilized precious metal catalysts enable extended catalyst lifecycle and simplified recovery compared to traditional batch approaches [55]. Researchers at Boehringer Ingelheim developed a palladium recovery system for Suzuki coupling reactions that recovered over 95% of the metal, significantly reducing lifecycle environmental impact [56].

Innovative approaches extend beyond simple recovery to transform waste streams into valuable inputs. Researchers demonstrated conversion of amide-containing pharmaceutical waste into nitrogen-enriched carbon materials for electrochemical applications [57]. Similarly, recovered phosphorous from pharmaceutical wastewater has been successfully repurposed as fertilizer, closing material loops between industries [58].

4.3. Energy Efficiency and Renewable Integration

Energy consumption represents a significant environmental impact throughout pharmaceutical manufacturing, from reaction heating and cooling to purification and facility operations. Sustainable approaches systematically reduce energy requirements while transitioning toward renewable energy sources that minimize carbon emissions [59]. These efforts align with broader industry commitments to climate action and greenhouse gas reduction targets.

Heat integration techniques optimize energy flows between process units, capturing waste heat from exothermic operations to support endothermic processes [60]. Novartis implemented a systematic heat recovery program across manufacturing facilities that reduced energy consumption by approximately 25% through innovations including waste heat boilers, heat exchangers, and thermal energy storage systems [61].

Renewable energy integration has accelerated across pharmaceutical manufacturing operations. Johnson & Johnson installed solar photovoltaic systems at multiple facilities, achieving on-site renewable generation exceeding 50% of electricity requirements at select manufacturing locations [62]. Similarly, AstraZeneca implemented renewable energy procurement strategies that achieved 100% renewable electricity across global operations through a combination of power purchase agreements and renewable energy certificates [63].

Table 3. Performance Metrics for Traditional and Sustainable Manufacturing Approaches

Manufacturing Aspect	Traditional Approach	Sustainable Approach	Performance Improvement	Industry Example
Process Design	Batch processing Multiple unit operations Extensive intermediate isolation	Continuous manufacturing Integrated processing Telescoped reactions	E-factor reduction: 60-90% PMI reduction: 50-85% Footprint reduction: 70-90%	Novartis (aliskiren): 90% footprint reduction, 83% PMI reduction Eli Lilly (ozanimod): 77% PMI reduction
Energy Utilization	High-temperature reactions Cryogenic cooling Conventional heating	Ambient temperature reactions Flow microreactors Alternative energy sources (photochemical, electrochemical)	Energy intensity reduction: 50-80% GHG emissions reduction: 40-70% Cooling requirements reduction: 60-90%	GSK (salmeterol): 75% energy reduction Merck (sitagliptin): 56% energy reduction
Solvent Usage	High volume solvent use Single-use application Hazardous solvent selection	Reduced solvent volumes Solvent recovery and reuse Green solvent substitution	Solvent volume reduction: 80-95% Virgin solvent reduction: 60-85% Hazardous waste reduction: 70-90%	Johnson & Johnson: 70% solvent recovery Pfizer (sertraline): 60% solvent reduction
Water Management	High water consumption Single-pass cooling Limited wastewater recovery	Process water reduction Closed-loop cooling Water recycling systems	Water consumption reduction: 50-80% Wastewater generation reduction: 60-90% Water quality improvement: 40-70%	Pfizer: 80% water reuse rate AstraZeneca: 80% water reduction in direct amination
Material Efficiency	Low atom economy Multiple purification steps High waste-to-product ratio	High atom economy processes Reduced purification requirements Byproduct valorization	Atom economy improvement: 30-60% Raw material reduction: 40-75% Waste generation reduction: 50-85%	Boehringer Ingelheim (nevirapine): 65% waste reduction Bristol-Myers Squibb (BMS-777607): 86% PMI reduction

Beyond facility energy, process innovations directly reduce energy requirements. Mechanochemical approaches perform reactions through mechanical force rather than thermal energy, eliminating heating requirements for compatible transformations [64]. Similarly, photocatalytic reactions utilizing LED light sources reduce energy consumption by 90% compared to traditional ultraviolet light processes while improving selectivity [65].

4.4. Water Conservation and Management

Pharmaceutical manufacturing traditionally consumes substantial water volumes for reaction media, extraction processes, equipment cleaning, and cooling systems. Sustainable approaches minimize water consumption through process redesign, closed-loop cooling systems, and advanced wastewater treatment enabling water reuse [66]. These efforts respond to increasing water scarcity concerns while reducing the environmental footprint associated with water treatment.

Process modifications demonstrably reduce water requirements. AstraZeneca researchers developed a catalytic direct amination process that eliminated an aqueous extraction step, reducing water consumption by approximately 80% for this transformation [67]. Similarly, continuous crystallization systems implemented by Novartis reduced cleaning water requirements by 90% compared to batch crystallization operations by eliminating between-batch cleaning cycles [68].

Water recycling systems treat process water for reuse in appropriate applications, creating cascading water systems where high-quality water is reserved for critical applications while treated water serves less demanding functions [69]. Pfizer implemented comprehensive water recycling at manufacturing facilities that achieved water reuse rates exceeding 80%, dramatically reducing freshwater demand [70]. These systems typically combine membrane filtration, advanced oxidation processes, and real-time monitoring to ensure water quality appropriate for intended applications.

Zero liquid discharge systems represent the frontier of pharmaceutical water management, treating and recycling all process water while recovering valuable materials from concentrate streams [71]. These systems typically combine multiple technologies including reverse osmosis, evaporation, and crystallization to eliminate liquid discharge while maximizing resource recovery. Though capital-intensive, these systems demonstrate particular value in water-stressed regions where regulatory requirements and water costs justify the investment [72].

5. Industry Standards

5.1. Evolving Regulatory Standards

Regulatory frameworks increasingly incorporate environmental considerations into pharmaceutical approval and manufacturing oversight processes. While historical regulations focused primarily on safety, efficacy, and quality parameters, contemporary frameworks have expanded to address environmental impacts throughout product lifecycles [73]. This evolution reflects growing recognition of pharmaceutical environmental impacts and public health implications of environmental contamination.

The European Medicines Agency (EMA) has pioneered environmental risk assessment requirements for new pharmaceutical products. The EMA guideline on environmental risk assessment requires comprehensive evaluation of environmental fate and effects for new active substances, using a tiered approach that escalates testing requirements based on initial findings [74]. This framework has catalyzed extensive research into pharmaceutical environmental impacts while encouraging development of less environmentally persistent compounds.

The U.S. Food and Drug Administration (FDA) has similarly increased emphasis on environmental considerations, particularly through the Quality by Design (QbD) initiative that encourages systematic evaluation of manufacturing processes. While not explicitly environmental in focus, QbD principles including process understanding, risk assessment, and continuous improvement facilitate development of more efficient, less wasteful manufacturing approaches [75]. Additionally, FDA guidance on continuous manufacturing has accelerated adoption of these more environmentally efficient technologies [76].

International Conference on Harmonisation (ICH) guidelines increasingly reference sustainability considerations, particularly in the Q11 guideline on development and manufacture of drug substances. This guideline explicitly acknowledges green chemistry principles and encourages evaluation of environmental impacts during manufacturing route selection [77]. The ongoing evolution of these frameworks suggests continued integration of sustainability parameters into global pharmaceutical regulatory systems.

5.2. Green Chemistry Metrics and Assessment Tools

Standardized metrics enable consistent evaluation of pharmaceutical processes against sustainability objectives, facilitating meaningful comparisons between synthetic routes and manufacturing approaches. The pharmaceutical industry has developed and implemented multiple metric systems that quantify environmental performance across diverse parameters [78].

Process Mass Intensity (PMI), which measures the ratio of total materials used to product mass, has emerged as a widely adopted primary metric [79]. This measure captures overall material efficiency without requiring detailed toxicity or environmental fate data, enabling straightforward calculation and comparison across processes. The American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable has promoted PMI alongside complementary metrics including carbon footprint and water intensity [80].

Life Cycle Assessment (LCA) methodologies provide more comprehensive environmental impact evaluation incorporating raw material extraction, manufacturing, distribution, use, and disposal phases [81]. While more resource-intensive than simplified metrics, LCA provides holistic understanding of environmental impacts across multiple categories including global warming potential, acidification, eutrophication, and resource depletion. GlaxoSmithKline has implemented streamlined LCA approaches for pharmaceutical manufacturing processes that balance comprehensive evaluation with practical implementation constraints [82].

Early-stage assessment tools enable integration of environmental considerations during research phases. Merck developed the "Green Scorecard" that evaluates candidate synthetic routes using multiple sustainability parameters, including reagent hazards, solvent selection, energy requirements, and waste generation [83]. Similarly, Pfizer's "GREENSCOPE" tool provides multidimensional sustainability assessment incorporating environmental, efficiency, energy, and economic factors to guide process development decisions [84].

5.3. Collaborative Initiatives and Public-Private Partnerships

Cross-sector collaborations have accelerated sustainable pharmaceutical development by pooling resources, sharing best practices, and developing pre-competitive research platforms. These initiatives overcome individual organization limitations through coordinated action addressing systemic challenges in pharmaceutical sustainability [85].

The ACS Green Chemistry Institute Pharmaceutical Roundtable exemplifies successful industry collaboration, bringing together pharmaceutical companies to establish research priorities, develop shared tools, and advance sustainable methodologies [86]. This initiative has funded numerous academic research projects developing green chemistry technologies while creating shared resources including solvent selection guides and environmental assessment tools [87].

Public-private partnerships extend collaborative approaches by incorporating regulatory agencies, academic institutions, and pharmaceutical companies into coordinated programs. The Innovative Medicines Initiative in Europe has supported multiple sustainability-focused projects, including ConcePTION (pharmaceutical environmental risk assessment methodologies) and CHEM21 (sustainable manufacturing technologies) [88]. These programs leverage complementary expertise while ensuring research addresses regulatory and commercial implementation considerations.

Academic-industry partnerships facilitate technology transfer from research institutions to manufacturing environments. The Engineering and Physical Sciences Research Council in the United Kingdom has funded multiple centres focusing on sustainable pharmaceutical manufacturing technologies, creating formal structures for academic-industry collaboration [89]. These centres develop fundamental technologies while providing training for scientists and engineers in sustainable approaches, building workforce capacity for future implementation.

5.4. Industry Leadership and Voluntary Standards

Leading pharmaceutical organizations have established voluntary sustainability commitments exceeding regulatory requirements, setting industry benchmarks while demonstrating commercial viability of sustainable approaches. These voluntary programs create market differentiation while accelerating adoption of sustainability practices industry-wide [90].

Science-based climate targets represent a prominent voluntary commitment area, with multiple pharmaceutical companies establishing greenhouse gas reduction goals aligned with Paris Agreement objectives [91]. Novartis committed to carbon neutrality across operations by 2025 and net-zero emissions across the value chain by 2040, implementing comprehensive programs spanning renewable energy procurement, energy efficiency, and supplier engagement [92]. Similarly, AstraZeneca established "Ambition Zero Carbon" targeting carbon neutrality by 2025 and negative carbon emissions by 2030 [93].

Water stewardship programs address pharmaceutical impacts on water resources through consumption reduction, wastewater quality improvement, and watershed protection initiatives. Johnson & Johnson implemented the "Water Risk Atlas" to identify manufacturing facilities in water-stressed regions, prioritizing conservation investments while establishing site-specific water reduction targets [94]. These programs typically extend beyond facility boundaries to engage local communities and protect watershed health.

Pharmaceutical supply chain standards increasingly incorporate sustainability requirements into supplier qualification and performance evaluation processes. The Pharmaceutical Supply Chain Initiative established shared supplier evaluation protocols that

include environmental management systems, waste reduction programs, and carbon emissions tracking [95]. These approaches leverage industry purchasing power to drive sustainability improvements beyond direct operations into extended supply networks.

Table 4. Comparative Analysis of International Regulatory Frameworks Addressing Pharmaceutical Environmental Impacts

Regulatory Framework	Region	Environmental Assessment Requirements	Implementation Stage	Industry Impact
EMA Environmental Risk Assessment Guideline	European Union	Tiered approach with PEC calculation Environmental fate and effects testing Risk quotient determination Risk mitigation measures	Mandatory for new marketing authorizations (2006) Required for significant variations	Extensive ecotoxicity data generation 40-70% more environmental testing Increased development costs (€100,000-€150,000 per compound) Early candidate screening for persistence
FDA Environmental Assessment Under NEPA	United States	Categorical exclusions for most pharmaceuticals Environmental assessments for specific cases Focus on manufacturing emissions Limited post-market requirements	Established regulatory framework Limited new drug application impact Increasing focus on manufacturing	Minimal impact on drug development Growing manufacturing site requirements Increased wastewater monitoring Limited influence on API design
PMDA Environmental Assessment Guidelines	Japan	Risk assessment for persistent substances Evaluation of bioaccumulation potential Focus on aquatic toxicity Limited terrestrial assessment	Developing framework Voluntary implementation Growing regulatory emphasis	Moderate impact on development Increasing data requirements Alignment with global development Focus on persistence reduction
ICH Q11 Development and Manufacture of Drug Substances	Global	Green chemistry principles recognition Process development considerations Quality risk management Design space approach	Established guidance Increasing environmental emphasis Industry-wide adoption	Systematic route selection processes Enhanced process understanding Improved manufacturing efficiency Reduced waste generation
Water Framework Directive (WFD)	European Union	Priority substance designation Environmental quality standards Monitoring requirements Emission control measures	Established framework Expanding pharmaceutical inclusion Increasing monitoring requirements	Significant post-market surveillance Growing manufacturing restrictions Increased wastewater treatment Strategic priority setting
Stockholm County Council Environmental Classification	Sweden	Environmental hazard classification Environmental risk ratings Persistence, bioaccumulation, toxicity Public disclosure requirements	Established voluntary system Influence on procurement Growing public awareness	Market access implications Formulary inclusion impact Transparency requirements Design influence for new APIs

6. Drug Lifecycle Management

6.1. Environmental Risk Assessment

Environmental risk assessment methodologies systematically evaluate potential ecological impacts throughout pharmaceutical lifecycles, from manufacturing releases to patient excretion and disposal [96]. These approaches combine exposure modeling with ecotoxicological evaluation to identify compounds requiring risk mitigation measures or alternative development pathways.

Exposure assessment methodologies predict environmental concentrations by modeling pharmaceutical fate through wastewater treatment systems and receiving environments [97]. These models incorporate pharmaceutical physicochemical properties, prescription volumes, metabolism data, and regional wastewater infrastructure to generate spatially resolved environmental concentration predictions. Advanced approaches incorporate seasonal variations in flow conditions, geographic differences in prescription patterns, and demographic changes affecting pharmaceutical consumption [98].

Ecotoxicological evaluation determines concentration thresholds where adverse effects occur across relevant species, typically following standardized testing protocols evaluating acute and chronic toxicity [99]. Contemporary approaches increasingly incorporate adverse outcome pathways linking molecular initiating events to population-level effects, enabling mechanism-based risk assessment that reduces animal testing requirements [100]. These approaches have particular value for pharmaceuticals with specific molecular targets where traditional ecotoxicological testing may overlook subtle but significant ecological effects.

Innovative risk assessment approaches address complexities specific to pharmaceutical environmental impacts. The eco-directed drug development concept integrates environmental considerations alongside traditional efficacy and safety parameters throughout the development process, enabling early identification of potentially problematic compounds [101]. Similarly, intelligent environmental assessment strategies use in silico methods to prioritize testing resources toward compounds and endpoints with highest potential concern [102].

6.2. Green Packaging and Distribution

Pharmaceutical packaging traditionally prioritized product protection and stability with limited consideration of environmental impacts. Contemporary approaches maintain these critical functions while reducing material consumption, incorporating recycled content, and designing for end-of-life recovery [103]. These innovations address the substantial waste stream generated by pharmaceutical packaging globally.

Material reduction strategies eliminate unnecessary packaging components while optimizing essential elements to minimize material consumption. Packaging redesign for blister packs has achieved material reductions exceeding 50% through elimination of unnecessary cardboard, optimization of cavity design, and minimization of blister package dimensions [104]. Similarly, concentrated formulations reduce both packaging materials and transportation impacts through reduced volume and weight.

Sustainable material selection increasingly incorporates recycled content, bio-based materials, and designs facilitating recycling [105]. GlaxoSmithKline implemented recycled polyethylene terephthalate (PET) for non-direct product contact applications, achieving approximately 40% recycled content across plastic packaging components [106]. Similarly, bio-based polymers derived from renewable feedstocks have demonstrated viability for pharmaceutical applications while reducing fossil carbon dependence [107].

Distribution system innovations reduce environmental impacts associated with product transportation and storage. Temperature-controlled shipping containers with phase-change materials have replaced dry ice for cold chain products, eliminating single-use expanded polystyrene while reducing weight [108]. Route optimization algorithms minimize transportation distances while maximizing vehicle utilization, reducing carbon emissions associated with product distribution [109].

6.3. End-of-Life Management and Take-Back Programs

Pharmaceutical waste from unused medications represents both an environmental concern and missed therapeutic opportunity. Sustainable approaches address this challenge through patient education, packaging design minimizing excess dispensing, and formal take-back programs enabling proper disposal [110]. These programs reduce environmental contamination while providing utilization data that informs prescribing practices.

Take-back programs enable consumers to return unused medications for proper disposal through incineration rather than flushing or landfill disposal that may contaminate water sources [111]. These programs vary from permanent collection receptacles in pharmacies to periodic collection events sponsored by community organizations or government agencies. Program effectiveness depends on consumer awareness, geographical access to collection points, and absence of participation barriers [112].

Extended producer responsibility frameworks establish formal pharmaceutical manufacturer obligations regarding product end-of-life management. The European Union has pioneered these approaches through directives requiring pharmaceutical manufacturers to fund and implement take-back programs [113]. These systems internalize environmental externalities associated with pharmaceutical disposal while creating incentives for designs minimizing unused medication volumes.

Packaging innovations facilitate appropriate disposal by incorporating clear instructions, providing separate compartments for different disposal requirements, and designing systems that reduce medication waste [114]. Unit-dose packaging reduces excess dispensing compared to bulk containers, particularly for acute medications where treatment duration varies [115]. Similarly, calendar packaging improves adherence while providing visual indication of medication consumption, reducing instances where patients inadvertently discontinue therapy and subsequently dispose of medications [116].

6.4. Post-Market Environmental Surveillance

Environmental monitoring programs track pharmaceutical concentrations in aquatic environments, providing real-world validation of risk assessment predictions while identifying emerging concerns requiring mitigation [117]. These programs have evolved from targeted studies of individual compounds toward comprehensive screening approaches capturing diverse pharmaceutical classes across multiple environmental compartments.

Surface water monitoring programs have documented widespread pharmaceutical presence in rivers, lakes, and coastal waters globally, with concentrations typically in the nanogram to microgram per liter range [118]. These studies utilize advances in analytical chemistry, particularly liquid chromatography coupled with tandem mass spectrometry, that enable detection of pharmaceuticals at environmentally relevant concentrations. Monitoring programs increasingly incorporate temporal sampling to capture seasonal variations and long-term trends that may indicate changing prescription patterns or environmental fate [119].

Sediment and biota sampling complements water monitoring by identifying compounds that bioaccumulate or adsorb to particulate matter [120]. These approaches have particular value for lipophilic pharmaceuticals that may achieve higher concentrations in organisms than surrounding waters. Fish tissue analysis has demonstrated bioaccumulation of multiple pharmaceutical classes, including antidepressants, antibiotics, and analgesics, with potential implications for aquatic ecosystem health [121].

Groundwater monitoring addresses concerns regarding pharmaceutical contamination of drinking water sources, particularly in regions relying on groundwater for municipal supply [122]. These programs have identified select pharmaceuticals in groundwater, though typically at lower concentrations than surface waters due to attenuation during soil passage. The long residence time of groundwater creates particular concern for persistent compounds that may accumulate over decades once contamination occurs [123].

7. Conclusion

The pharmaceutical industry stands amid a fundamental transformation where traditional approaches prioritizing therapeutic innovation at environmental expense yield to integrated paradigms balancing human health and ecological wellbeing. This transition reflects growing recognition that pharmaceutical environmental impacts potentially undermine the very health objectives these products aim to address. Significant progress has occurred across multiple domains. Green chemistry principles have revolutionized synthetic approaches through biocatalysis, flow chemistry, and solvent optimization that dramatically reduce waste generation while improving efficiency. Computational methods including virtual screening, molecular modeling, and machine learning accelerate discovery while minimizing physical material requirements. Manufacturing innovations spanning process intensification, circular approaches, and energy optimization have transformed production systems toward greater sustainability. These advances have demonstrated that environmental objectives need not conflict with therapeutic innovation when sustainability principles integrate throughout development pathways. Indeed, many sustainable approaches simultaneously improve efficiency, reduce costs, and enhance quality while minimizing environmental impacts. The most successful implementations view sustainability not as regulatory compliance burden but as innovation catalyst driving competitive advantage.

References

[1] Kümmerer K. Sustainable chemistry: a future guiding principle. Angew Chem Int Ed. 2017;56(52):16420-16421.

[2] Sheldon RA. The E factor 25 years on: the rise of green chemistry and sustainability. Green Chem. 2017;19(1):18-43.

[3] Daughton CG, Ternes TA. Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ Health Perspect. 1999;107(Suppl 6):907-938.

[4] Jiménez-González C, Ponder CS, Broxterman QB, Manley JB. Using the right green yardstick: why process mass intensity is used in the pharmaceutical industry to drive more sustainable processes. Org Process Res Dev. 2011;15(4):912-917.

[5] Belkhir L, Elmeligi A. Carbon footprint of the global pharmaceutical industry and relative impact of its major players. J Clean Prod. 2019;214:185-194.

[6] Zimmerman JB, Anastas PT, Erythropel HC, Leitner W. Designing for a green chemistry future. Science. 2020;367(6476):397-400.

[7] Ott D, Kralisch D, Denčić I, Hessel V, Laribi Y, Perrichon PD, et al. Life cycle analysis within pharmaceutical process optimization and intensification: case study of active pharmaceutical ingredient production. ChemSusChem. 2014;7(12):3521-3533.

[8] Tucker JL, Faul MM. Industrial research: drug companies must adopt green chemistry. Nature. 2016;534(7605):27-29.

[9] Genheden S, Reymond JL. Artificial intelligence in drug discovery: what is realistic, what are illusions? Reality and expectations from a medicinal chemist perspective. Future Med Chem. 2020;12(20):1851-1864.

[10] Poechlauer P, Colberg J, Fisher E, Jansen M, Johnson MD, Koenig SG, et al. Pharmaceutical roundtable study demonstrates the value of continuous manufacturing in the design of greener processes. Org Process Res Dev. 2013;17(12):1472-1478.

[11] Anastas PT, Warner JC. Green chemistry: theory and practice. Oxford: Oxford University Press; 1998.

[12] Constable DJC, Curzons AD, Cunningham VL. Metrics to 'green' chemistry - which are the best? Green Chem. 2002;4(6):521-527.

[13] Alfonsi K, Colberg J, Dunn PJ, Fevig T, Jennings S, Johnson TA, et al. Green chemistry tools to influence a medicinal chemistry and research chemistry based organisation. Green Chem. 2008;10(1):31-36.

[14] Dunn PJ, Galvin S, Hettenbach K. The development of an environmentally benign synthesis of sildenafil citrate (Viagra™) and its assessment by green chemistry metrics. Green Chem. 2004;6(1):43-48.

[15] Savile CK, Janey JM, Mundorff EC, Moore JC, Tam S, Jarvis WR, et al. Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture. Science. 2010;329(5989):305-309.

[16] Bornscheuer UT, Huisman GW, Kazlauskas RJ, Lutz S, Moore JC, Robins K. Engineering the third wave of biocatalysis. Nature. 2012;485(7397):185-194.

[17] Arnold FH. Innovation by evolution: bringing new chemistry to life (Nobel Lecture). Angew Chem Int Ed. 2019;58(41):14420-14426.

[18] Huffman MA, Fryszkowska A, Alvizo O, Borra-Garske M, Campos KR, Canada KA, et al. Design of an in vitro biocatalytic cascade for the manufacture of islatravir. Science. 2019;366(6470):1255-1259.

[19] Truppo MD, Strotman H, Hughes G. Development of an immobilized transaminase capable of operating in organic solvent. ChemCatChem. 2012;4(8):1071-1074.

[20] Plutschack MB, Pieber B, Gilmore K, Seeberger PH. The Hitchhiker's guide to flow chemistry. Chem Rev. 2017;117(18):11796-11893.

[21] Adamo A, Beingessner RL, Behnam M, Chen J, Jamison TF, Jensen KF, et al. On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system. Science. 2016;352(6281):61-67.

[22] Cole KP, Groh JM, Johnson MD, Burcham CL, Campbell BM, Diseroad WD, et al. Kilogram-scale prexasertib monolactate monohydrate synthesis under continuous-flow CGMP conditions. Science. 2017;356(6343):1144-1150.

[23] Cambié D, Bottecchia C, Straathof NJW, Hessel V, Noël T. Applications of continuous-flow photochemistry in organic synthesis, material science, and water treatment. Chem Rev. 2016;116(17):10276-10341.

[24] Pletcher D, Green RA, Brown RCD. Flow electrolysis cells for the synthetic organic chemistry laboratory. Chem Rev. 2018;118(9):4573-4591.

[25] Byrne FP, Jin S, Paggiola G, Petchey THM, Clark JH, Farmer TJ, et al. Tools and techniques for solvent selection: green solvent selection guides. Sustain Chem Process. 2016;4(1):7.

[26] Diorazio LJ, Hose DRJ, Adlington NK. Toward a more holistic framework for solvent selection. Org Process Res Dev. 2016;20(4):760-773.

[27] Alder CM, Hayler JD, Henderson RK, Redman AM, Shukla L, Shuster LE, et al. Updating and further expanding GSK's solvent sustainability guide. Green Chem. 2016;18(13):3879-3890.

[28] Clarke CJ, Tu WC, Levers O, Bröhl A, Hallett JP. Green and sustainable solvents in chemical processes. Chem Rev. 2018;118(2):747-800.

[29] Tan D, Friščić T. Mechanochemistry for organic chemists: an update. Eur J Org Chem. 2018;2018(1):18-33.

[30] Jessop PG, Mercer SM, Heldebrant DJ. CO2-triggered switchable solvents, surfactants, and other materials. Energy Environ Sci. 2012;5(6):7240-7253.

[31] Jadhav SA, Dhavale DD, Markad SD, Dhanavade MJ, Sonawane KD. Greener approach toward the facile synthesis of 1,4-disubstituted 1,2,3-triazoles as potential antifungal agents. ACS Sustain Chem Eng. 2018;6(12):16006-16013.

[32] Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmacol Rev. 2014;66(1):334-395.

[33] Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov. 2011;10(3):188-195.

[34] Jiménez-Luna J, Grisoni F, Weskamp N, Schneider G. Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opin Drug Discov. 2021;16(9):949-959.

[35] Nguyen DD, Gao K, Chen J, Wang R, Wei GW. Potentially highly potent drugs for 2019-nCoV. bioRxiv [Preprint]. 2020 Feb 13:2020.02.05.936013.

[36] De Vivo M, Masetti M, Bottegoni G, Cavalli A. Role of molecular dynamics and related methods in drug discovery. J Med Chem. 2016;59(9):4035-4061.

[37] Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247-262.

[38] Wang L, Wu Y, Deng Y, Kim B, Pierce L, Krilov G, et al. Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. J Am Chem Soc. 2015;137(7):2695-2703.

[39] Abel R, Wang L, Harder ED, Berne BJ, Friesner RA. Advancing drug discovery through enhanced free energy calculations. Acc Chem Res. 2017;50(7):1625-1632.

[40] Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80-93.

[41] Sarella PN, Mangam VT. AI-Driven Natural Language Processing in Healthcare: Transforming Patient-Provider Communication. Indian Journal of Pharmacy Practice. 2024;17(1).

[42] Wenzel J, Matter H, Schmidt F. Predictive multitask deep neural network models for ADME-Tox properties: learning from large data sets. J Chem Inf Model. 2019;59(3):1253-1268.

[43] Schwaller P, Laino T, Gaudin T, Bolgar P, Hunter CA, Bekas C, et al. Molecular transformer: a model for uncertainty-calibrated chemical reaction prediction. ACS Cent Sci. 2019;5(9):1572-1583.

[44] Keshavarzi Arshadi A, Salem M, Collins J, Yuan JS, Chakrabarti D. DeepMalaria: artificial intelligence driven discovery of potent antiplasmodials. Front Pharmacol. 2020;10:1526.

[45] Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37(9):1038-1040.

[46] Jayatunga MKP, Xie W, Ruder L, Schulze U, Meier C. AI in small-molecule drug discovery: a coming wave? Nat Rev Drug Discov. 2022;21(3):175-176.

[47] Coley CW, Thomas DA, Lummiss JAM, Jaworski JN, Breen CP, Schultz V, et al. A robotic platform for flow synthesis of organic compounds informed by AI planning. Science. 2019;365(6453):eaax1566.

[48] Stankiewicz AI, Moulijn JA. Process intensification: transforming chemical engineering. Chem Eng Prog. 2000;96(1):22-34.

[49] Mascia S, Heider PL, Zhang H, Lakerveld R, Benyahia B, Barton PI, et al. End-to-end continuous manufacturing of pharmaceuticals: integrated synthesis, purification, and final dosage formation. Angew Chem Int Ed. 2013;52(47):12359-12363.

[50] Rogers L, Briggs N, Achermann R, Adamo A, Azad M, Brancazio D, et al. Continuous production of five active pharmaceutical ingredients in flexible plug-and-play modules: a demonstration campaign. Org Process Res Dev. 2020;24(10):2183-2196.

[51] Porta R, Benaglia M, Puglisi A. Flow chemistry: recent developments in the synthesis of pharmaceutical products. Org Process Res Dev. 2016;20(1):2-25.

[52] Clark JH, Farmer TJ, Hunt AJ, Sherwood J. Opportunities for bio-based solvents created as petrochemical and fuel products transition towards renewable resources. Int J Mol Sci. 2015;16(8):17101-17159.

[53] Dunn PJ, Wells A, Williams MT, editors. Green chemistry in the pharmaceutical industry. Weinheim: Wiley-VCH; 2010.

[54] Raymond MJ, Slater CS, Savelski MJ. LCA approach to the analysis of solvent waste issues in the pharmaceutical industry. Green Chem. 2010;12(10):1826-1834.

[55] Vural Gürsel I, Noel T, Wang Q, Hessel V. Separation/recycling methods for homogeneous transition metal catalysts in continuous flow. Green Chem. 2015;17(4):2012-2026.

[56] Gürsel IV, Aldiansyah F, Wang Q, Noël T, Hessel V. Continuous metal scavenging and coupling to one-pot copper-catalyzed azide-alkyne cycloaddition click reaction in flow. Chem Eng J. 2015;270:468-475.

[57] Dong H, Thunberg J, Sehaqui H, Bussy C, Allais M, Deutsch S, et al. Green and facile fabrication of nitrogen-doped porous carbonaceous microparticles from waste pharmaceutical cotton. Cellulose. 2015;22(6):3623-3635.

[58] Mayer BK, Baker LA, Boyer TH, Drechsel P, Gifford M, Hanjra MA, et al. Total value of phosphorus recovery. Environ Sci Technol. 2016;50(13):6606-6620.

[59] Galán-Martín Á, Pozo C, Azapagic A, Grossmann IE, Mac Dowell N, Guillén-Gosálbez G. Time for global action: an optimised cooperative approach towards effective climate change mitigation. Energy Environ Sci. 2018;11(3):572-581.

[60] Jiménez-González C, Constable DJC, editors. Green chemistry and engineering: a practical design approach. Hoboken: John Wiley & Sons; 2011.

[61] Smith CJ, Nikbin N, Ley SV, Lange H, Baxendale IR. A fully automated, multistep flow synthesis of 5-amino-4-cyano-1,2,3-triazoles. Org Biomol Chem. 2011;9(6):1938-1947.

[62] Goldsmith BR, Esterhuizen J, Liu JX, Bartel CJ, Sutton C. Machine learning for heterogeneous catalyst design and discovery. AIChE J. 2018;64(7):2311-2323.

[63] Reid G, Sturm B. Supply chain management for sustainable chemical products. In: Abraham MA, editor. Encyclopedia of sustainable technologies. Oxford: Elsevier; 2017. p. 213-220.

[64] Tan D, García F. Main group mechanochemistry: from curiosity to established protocols. Chem Soc Rev. 2019;48(8):2274-2292.

[65] Romero NA, Nicewicz DA. Organic photoredox catalysis. Chem Rev. 2016;116(17):10075-10166.

[66] Grant SB, Saphores JD, Feldman DL, Hamilton AJ, Fletcher TD, Cook PLM, et al. Taking the "waste" out of "wastewater" for human water security and ecosystem sustainability. Science. 2012;337(6095):681-686.

[67] Prat D, Pardigon O, Flemming HW, Letestu S, Ducandas V, Isnard P, et al. Sanofi's solvent selection guide: a step toward more sustainable processes. Org Process Res Dev. 2013;17(12):1517-1525.

[68] Gutmann B, Cantillo D, Kappe CO. Continuous-flow technology—a tool for the safe manufacturing of active pharmaceutical ingredients. Angew Chem Int Ed. 2015;54(23):6688-6728.

[69] Tian C, Sun C, Liao W, Yang R, Zhou J, Liu J. Treatment and resource recovery from wastewater by membrane technologies. Water Sci Technol. 2021;83(9):2063-2078.

[70] Tallentire CW, Steubing B. The environmental benefits of improving packaging waste collection in Europe. Waste Manag. 2020;103:426-436.

[71] Tong T, Elimelech M. The global rise of zero liquid discharge for wastewater management: drivers, technologies, and future directions. Environ Sci Technol. 2016;50(13):6846-6855.

[72] Subramani A, Jacangelo JG. Emerging desalination technologies for water treatment: a critical review. Water Res. 2015;75:164-187.

[73] Ågerstrand M, Berg C, Björlenius B, Breitholtz M, Brunström B, Fick J, et al. Improving environmental risk assessment of human pharmaceuticals. Environ Sci Technol. 2015;49(9):5336-5345.

[74] European Medicines Agency. Guideline on the environmental risk assessment of medicinal products for human use. EMEA/CHMP/SWP/4447/00 Rev. 1. London: European Medicines Agency; 2018.

[75] Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771-783.

[76] Lee SL, O'Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov. 2015;10(3):191-199.

[77] International Conference on Harmonisation. ICH harmonised tripartite guideline: development and manufacture of drug substances (chemical entities and biotechnological/biological entities) Q11. Geneva: ICH; 2012.

[78] Jiménez-González C, Curzons AD, Constable DJC, Cunningham VL. Expanding GSK's solvent selection guide – application of life cycle assessment to enhance solvent selections. Clean Technol Environ Policy. 2005;7(1):42-50.

[79] Roschangar F, Sheldon RA, Senanayake CH. Overcoming barriers to green chemistry in the pharmaceutical industry – the Green Aspiration Level™ concept. Green Chem. 2015;17(2):752-768.

[80] Jiménez-González C, Poechlauer P, Broxterman QB, Yang BS, am Ende D, Baird J, et al. Key green engineering research areas for sustainable manufacturing: a perspective from pharmaceutical and fine chemicals manufacturers. Org Process Res Dev. 2011;15(4):900-911.

[81] Cespi D, Beach ES, Swarr TE, Passarini F, Vassura I, Dunn PJ, et al. Life cycle inventory improvement in the pharmaceutical sector: assessment of the sustainability combining PMI and LCA tools. Green Chem. 2015;17(6):3390-3400.

[82] Watson S, Drabik M, Hahladakis J, Iacovidou E, Purnell P. Sustainable pharmaceutical supply chains: the role of circular economy principles. Sustain Prod Consum. 2022;35:435-450.

[83] Cue BW, Zhang J. Green process chemistry in the pharmaceutical industry. Green Chem Lett Rev. 2009;2(4):193-211.

[84] García-Serna J, Pérez-Barrigón L, Cocero MJ. New trends for design towards sustainability in chemical engineering: green engineering. Chem Eng J. 2007;133(1-3):7-30.

[85] Constable DJC, Dunn PJ, Hayler JD, Humphrey GR, Leazer JL Jr, Linderman RJ, et al. Key green chemistry research areas—a perspective from pharmaceutical manufacturers. Green Chem. 2007;9(5):411-420.

[86] Bryan MC, Dunn PJ, Entwistle D, Gallou F, Koenig SG, Hayler JD, et al. Key Green Chemistry research areas from a pharmaceutical manufacturers' perspective revisited. Green Chem. 2018;20(22):5082-5103.

[87] Caron I, Keizers PHJ, van Schril MAS, van den Berg RJW, Jacobs A, Schenk G. Green chemistry in pharmaceutical analysis. Green Chem. 2021;23(20):8045-8068.

[88] Petermeijer J, Belderbos S, Olubummo A, Vandt JA, Baart MJ, van Rixel VHS, et al. European initiatives driving sustainable healthcare: Innovative Medicines Initiative (IMI). Drug Discov Today. 2021;26(8):1909-1913.

[89] Balu AM, Budarin V, Shuttleworth PS, Pfaltzgraff LA, Waldron K, Luque R, et al. Valorisation of orange peel residues: waste to biochemicals and nanoporous materials. ChemSusChem. 2012;5(9):1694-1697.

[90] Eckelman MJ, Sherman JD. Estimated global disease burden from US health care sector greenhouse gas emissions. Am J Public Health. 2018;108(S2):S120-S122.

[91] Belkhir L, Bernard S, Elmeligi A. Carbon footprint of the global healthcare sector: a modeling study. Lancet Planet Health. 2021;5(12):e840-e847.

[92] Hasegawa T, Onishi H, Takagi T, Morikane K. The science-based target initiative and the healthcare sector: an analysis of carbon reduction target setting for hospitals. Glob Health Med. 2022;4(5):275-282.

[93] Thornton G, Monge-Narajo A, Montero-Odio P, Ramírez-Hernández O, Jiménez-Ruiz R. Quantification of greenhouse gas emissions in a pharmaceutical industry in Costa Rica and proposal for a low-carbon certification. Sustainability. 2022;14(3):1176.

[94] Corcoran E, Nellemann C, Baker E, Bos R, Osborn D, Savelli H, editors. Sick water? The central role of wastewater management in sustainable development. A rapid response assessment. Nairobi: United Nations Environment Programme; 2010.

[95] Yakovleva N, Sarkis J, Sloan T. Sustainable benchmarking of supply chains: the case of the food industry. Int J Prod Res. 2012;50(5):1297-1317.

[96] Kümmerer K. Pharmaceuticals in the environment: sources, fate, effects and risks. 3rd ed. Berlin: Springer; 2008.

[97] Burns EE, Carter LJ, Kolpin DW, Thomas-Oates J, Boxall ABA. Temporal and spatial variation in pharmaceutical concentrations in an urban river system. Water Res. 2018;137:72-85.

[98] Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ. The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK. Water Res. 2008;42(13):3498-3518.

[99] Brausch JM, Connors KA, Brooks BW, Rand GM. Human pharmaceuticals in the aquatic environment: a review of recent toxicological studies and considerations for toxicity testing. Rev Environ Contam Toxicol. 2012;218:1-99.

[100] Allen TEH, Goodman JM, Gutsell S, Russell PJ. Defining molecular initiating events in the adverse outcome pathway framework for risk assessment. Chem Res Toxicol. 2014;27(12):2100-2112.

[101] Kümmerer K, Hempel M, editors. Green and sustainable pharmacy. Berlin: Springer; 2010.

[102] Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DGJ. Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. Environ Sci Technol. 2008;42(15):5807-5813.

[103] García-Arca J, González-Portela Garrido AT, Prado-Prado JC. Sustainable packaging logistics. The link between sustainability and competitiveness in supply chains. Sustainability. 2017;9(7):1098.

[104] Marsh K, Bugusu B. Food packaging—roles, materials, and environmental issues. J Food Sci. 2007;72(3):R39-R55.

[105] Risch SJ. Food packaging history and innovations. J Agric Food Chem. 2009;57(18):8089-8092.

[106] Emblem A, Emblem H. Packaging technology: fundamentals, materials and processes. Cambridge: Woodhead Publishing; 2012.

[107] Yates MR, Barlow CY. Life cycle assessments of biodegradable, commercial biopolymers—a critical review. Resour Conserv Recycl. 2013;78:54-66.

[108] Ohtake S, Izutsu K, Lechuga-Ballesteros D. Practical considerations for formulation development of freeze-dried biologics. AAPS J. 2011;13(2):241-249.

[109] Srivastava SK. Green supply-chain management: a state-of-the-art literature review. Int J Manag Rev. 2007;9(1):53-80.

[110] Kotchen M, Kallaos J, Wheeler K, Wong C, Zahller M. Pharmaceuticals in wastewater: behavior, preferences, and willingness to pay for a disposal program. J Environ Manage. 2009;90(3):1476-1482.

[111] Tong AYC, Peake BM, Braund R. Disposal practices for unused medications around the world. Environ Int. 2011;37(1):292-298.

[112] Law AV, Sakharkar P, Zargarzadeh A, Tai BWB, Hess K, Hata M, et al. Taking stock of medication wastage: unused medications in US households. Res Social Adm Pharm. 2015;11(4):571-578.

[113] Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. OJ L 136, 30.4.2004, p. 34-57.

[114] Lockwood C, Pitsillides A, Farrow E. The environmental fate of package inserts that accompany prescription drugs: disposing of the paper trail. Pharm J. 2002;268(7188):232-233.

[115] Mahatanankoon P, Vila-Brunet N. Consumer reactions to medication waste: a conceptual framework. J Pharm Pract. 2019;32(5):527-534.

[116] Gerlach KK, Marino C, Hoffman-Goetz L. Lack of adherence to Canadian newspaper recommendations for sun protection in articles. Chronic Dis Can. 2009;29(3):123-131.

[117] Petrie B, Barden R, Kasprzyk-Hordern B. A review on emerging contaminants in wastewaters and the environment: current knowledge, understudied areas and recommendations for future monitoring. Water Res. 2015;72:3-27.

[118] Loos R, Carvalho R, António DC, Comero S, Locoro G, Tavazzi S, et al. EU-wide monitoring survey on emerging polar organic contaminants in wastewater treatment plant effluents. Water Res. 2013;47(17):6475-6487.

[119] Riva F, Zuccato E, Castiglioni S. Prioritization and analysis of pharmaceuticals for human use contaminating the aquatic ecosystem in Italy. J Pharm Biomed Anal. 2015;106:71-78.

[120] Zenker A, Cicero MR, Prestinaci F, Bottoni P, Carere M. Bioaccumulation and biomagnification potential of pharmaceuticals with a focus to the aquatic environment. J Environ Manage. 2014;133:378-387.

[121] McEneff G, Barron L, Kelleher B, Paull B, Quinn B. A year-long study of the spatial occurrence and relative distribution of pharmaceutical residues in sewage effluent, receiving marine waters and marine bivalves. Sci Total Environ. 2014;476-477:317-326.

[122] Lapworth DJ, Baran N, Stuart ME, Ward RS. Emerging organic contaminants in groundwater: a review of sources, fate and occurrence. Environ Pollut. 2012;163:287-303.

[123] Sui Q, Cao X, Lu S, Zhao W, Qiu Z, Yu G. Occurrence, sources and fate of pharmaceuticals and personal care products in the groundwater: a review. Emerg Contam. 2015;1(1):14-24.